Huahai Pharmaceutical Subsidiaries Receive Approval to Initiate Clinical Trials of HB0056 Injection for Atopic Dermatitis

Gelonghui February 9th |Huahai PharmaceuticalAnnouncement, Subsidiary Shanghai HuaHuaota BiopharmaceuticalShanghai Huaota Biopharmaceutical Co., Ltd. and Huabo Biopharm Co., Ltd. have received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the new additional indications of the HB0056 injection project. The indication for HB0056 injection is atopic dermatitis, with the dosage form being an injectable solution, and the application matter being a clinical trial. The clinical trial application submitted by the applicants, Shanghai Huaota Biopharmaceutical Co., Ltd. and Huabo Biopharm Co., Ltd., has been accepted by the National Medical Products Administration, which has agreed to proceed with the clinical trial for the new additional indications. To date, the company has invested approximately RMB 91.69 million in research and development expenses for the HB0056 project.